This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Savient Pharmaceuticals, Inc. (SVNT)
Q2 2012 Earnings Call
August 08, 2012 09:00 a.m. ET
Louis Ferrari – President and Chief Executive Officer
Richard Crowley – EVP, Biopharmaceutical Operations
Philip Yachmetz – SVP, General Counsel
Kenneth Bahrt – SVP, Chief Medical Officer
David Gionco – Chief Accounting Officer
Eric Schmidt – Cowen and Company
Cory Kasimov – JP Morgan
Katherine Xu – William Blair
David Krempa – Morning Star
Tazeen Ahmad – Bank of America
Rahul Jasuja – Noble Financial
Carol Werther – Summer Street Research
Heather Behanna – JMP Securities
Good day ladies and gentlemen, and thank you for standing by. Welcome to the Savient Pharmaceuticals second quarter 2012 financial results conference call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session. As a reminder this conference will be recorded.
I would now like to introduce your host for today, Mr. Philip Yachmetz, Senior Vice President and General Counsel for Savient Pharmaceuticals. Sir, please begin.
Thank you and good morning. Welcome to Savient Pharmaceuticals second quarter 2012 financial results conference call. This morning we issued a press release providing financial results and highlights for the second quarter of 2012. The press release is available on our website at www.savient.com.
Before today’s call, I would like to read our Safe Harbor statement. Comments made during this conference call will contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of Savient Pharmaceuticals.